Source comparison
Effectiveness Comparison
Clinical efficacy data reveals significant differences in growth hormone-releasing potency between Ipamorelin and GHRP-2. In the landmark study by Raun et al., GHRP-2 at 1 mcg/kg bodyweight produced mean peak GH levels of 23.4 ± 4.2 ng/mL in healthy adults, wh
This comparison does not assign a generated winner or score.
- Clinical efficacy data reveals significant differences in growth hormone-releasing potency between Ipamorelin and GHRP-2. In the landmark study by Raun et al., GHRP-2 at 1 mcg/kg bodyweight produced mean peak GH levels of 23.4 ± 4.2 ng/mL in healthy adults, while equivalent Ipamorelin dosing achieved 11.8 ± 2.1 ng/mL[24]. The area under the curve (AUC) for growth hormone release was 1.8-fold higher with GHRP-2 over the 4-hour measurement period[25].
- Peak GH Level (ng/mL)
- 11.8 ± 2.1
- 23.4 ± 4.2
- <0.001
- Time to Peak (min)
- 35 ± 8
- 32 ± 6
- 0.23
- Duration >5 ng/mL (hours)
- 2.4 ± 0.6
- 3.2 ± 0.8
- <0.01
- AUC 0-4h (ng·h/mL)
- 28.5 ± 5.2
- 51.2 ± 9.1
- Long-term efficacy studies demonstrate sustained growth hormone responses with both peptides over 12-week treatment periods. The European Growth Hormone Study Group reported that GHRP-2 maintained 85% of initial GH-releasing capacity after 84 days of daily administration, while Ipamorelin retained 92% of baseline response[26]. This suggests Ipamorelin may have less receptor desensitization over extended treatment periods.
- IGF-1 elevation, a key downstream marker of growth hormone activity, shows dose-dependent increases with both peptides. GHRP-2 at 200 mcg twice daily increased serum IGF-1 by 42% ± 12% from baseline after 8 weeks, compared to 28% ± 8% with Ipamorelin 300 mcg twice daily[27]. However, the IGF-1 response per unit of growth hormone released was similar between compounds, indicating equivalent biological activity once GH is secreted[28].